Skip to main navigation Skip to search Skip to main content

Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer

  • Ying Yang
  • , Qiang Liu
  • , Xinyan Li
  • , Hua Zhang
  • , Xin Xu
  • , Qi Ma
  • , Somaira Nowsheen
  • , Khaled Aziz
  • , Ye Xiong Li
  • , Zhenkun Lou
  • , Qiuzi Zhong
  • , Min Deng

Research output: Contribution to journal › Article › peer-review

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) progresses aggressively and resists existing therapies. Although poly(ADP-ribose) polymerase inhibitors (PARPis) benefit a subset of patients with mCRPC and BRCA1/2 deficiencies, therapeutic options remain limited for those without such mutations. Here, we uncover a critical role for the ATM-TRMT10A-BRCA1 signaling axis in regulating homologous recombination (HR) repair and PARPi sensitivity. We demonstrate that ATM phosphorylates TRMT10A at serine-28 after DNA damage, promoting BRCA1 recruitment and efficient HR repair. TRMT10A deletion disrupts HR repair, sensitizing cells to PARPis. Moreover, TRMT10A is up-regulated in mCRPC through stabilization by USP10. Targeting USP10 with spautin-1 induces TRMT10A degradation and enhances tumor sensitivity to PARPis in cell-derived xenografts and patient-derived xenograft models. These findings identify TRMT10A as a therapeutic vulnerability in mCRPC and demonstrate that combined inhibition of PARP and USP10 offers a promising synthetic lethal strategy for a broader group of patients lacking classical BRCA mutations.

Original languageEnglish (US)
Pages (from-to)eadw7989
JournalScience Advances
Volume11
Issue number41
DOIs
StatePublished - Oct 10 2025

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Targeting the ATM-TRMT10A-BRCA1 axis confers synthetic lethality to PARP inhibition in metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this